TP53 gene and p53 protein vs. endometrial carcinoma;Gen TP53 i białko p53 a rak błony śluzowej trzonu macicy

Przeglad Menopauzalny

Volumn 17, Issue 3, 2013, Pages 228-230

  Zaja̧c, Agnieszka ^a   Stachowiak, Grzegorz ^a   Stetkiewicz, Tomasz ^a   Wilczyński, Jacek R ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Endometrial carcinoma; Menopause; P53; TP53

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE; DNA REPAIR; ENDOMETRIUM CARCINOMA; GENE; GENE EXPRESSION; HUMAN; PROTEIN EXPRESSION; TP53 GENE; TUMOR DIFFERENTIATION;

EID: 84884472978     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: 10.5114/pm.2013.36588     Document Type: Article

References (15)

1. Zaja̧c A., Pertyński T. Polimorfizm genu MDM2 a ryzyko wysta̧pienia raka endometrium. Prz Menopauz 2009; 13: 269-72.
2. Sobczuk A, Romanowicz-Makowska H, Pertyński T. Ekspresja genu MMAC/PTEN w raku endometrium - badania RT-PCR. Prz Menopauz 2007; 11: 344-6. (Pubitemid 351166357)
3. Schafer KA. The cell cycle: a review. Vet Pathol 1998; 35: 461-78. (Pubitemid 128472819)
4. Hainaut P. TP53: Coordinator of the Processes That Underlie the Hallmarks of Cancer. In: p53 in the Clinics. Pierre H, Magali O, Klas GW (eds.). Springer, New York 2013; 1-23.
5. Li FP, Fraumeni Jr J F. Soft-tissue sarcomas, breast cancer and other neoplasms: a familial syndrome? Ann Intern Med 1969; 71: 747-52.
6. th ed. W.B. Saunders, Philadelphia 2010; 288-90.
7. Prives C, Hall PA The p53 pathway. J Pathol 1999; 187: 112-26. (Pubitemid 29009841)
8. Schmitt CA, Fridman JS, Yang M, et al Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1: 289-98. (Pubitemid 41039153)
9. Hu W, Feng Z, Ma L., et al A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 2007; 67: 2757-65. (Pubitemid 46548964)
10. Yoneda T, Kuboyama A, Kato K., et al Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep 2013; 30: 25-34.
11. Ohgami T, Kato K, Kobayashi H., et al Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers. Cancer Sci 2010; 101: 1387-95.
12. Daniilidou K, Frangou-Plemenou M, Grammatikakis J., et al Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study. J BUON 2013; 18: 195-201.
13. Yoshida M, Katsuda S, Maekawa A. Involvements of estrogen receptor, proliferating cell nuclear antigen and p53 in endometrial adenocarcinoma development in Donryu rats. J Toxicol Pathol 2012; 25: 241-7.
14. O'Hara A.J., Bell DW The genomics and genetics of endometrial cancer. Adv Genomics Genet 2012; 2012: 33-47.
15. Akbay EA, Peña CG, Ruder D., et al Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis. Oncogene 2013; 32: 2211-9.